{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:17:39Z","timestamp":1788297459047,"version":"build-2803163510"},"reference-count":76,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003980","name":"Istituto Toscano Tumori","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003980","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009888","name":"Tuscany Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bbadis.2025.167975","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T11:14:46Z","timestamp":1751886886000},"page":"167975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["ETV4 and ETV1-mediated downregulation of the secretory leukocyte protease inhibitor contributes to the indolent phenotype of early-stage prostate cancer"],"prefix":"10.1016","volume":"1871","author":[{"given":"Irene","family":"Cosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Moccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Nannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Rosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Iozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Luceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Notaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Angioletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2025.167975_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbadis.2025.167975_bb0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-077738","article-title":"Prostate cancer incidence and mortality in Europe and implications for screening activities: population based study","volume":"386","author":"Vaccarella","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.bbadis.2025.167975_bb0015","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1056\/NEJMe2300807","article-title":"Localized prostate Cancer - then and now","volume":"388","author":"Sartor","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2025.167975_bb0020","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMc2406108","article-title":"Radical prostatectomy or watchful waiting in early prostate Cancer","volume":"391","author":"Holmberg","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bbadis.2025.167975_bb0025","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bbadis.2025.167975_bb0030","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2025.167975_bb0035","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science (N. Y.)."},{"key":"10.1016\/j.bbadis.2025.167975_bb0040","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrc.2017.20","article-title":"The ETS family of oncogenic transcription factors in solid tumours","volume":"17","author":"Sizemore","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbadis.2025.167975_bb0045","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/978-3-030-32656-2_18","article-title":"Oncogenic ETS factors in prostate Cancer","volume":"1210","author":"Nicholas","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.bbadis.2025.167975_bb0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.canlet.2022.01.009","article-title":"ETS factors in prostate cancer","volume":"530","author":"Qian","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbadis.2025.167975_bb0055","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2025.167975_bb0060","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nature06024","article-title":"Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer","volume":"448","author":"Tomlins","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2025.167975_bb0065","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0964-1955(97)00047-X","article-title":"Expression of E1AF, an ets-family transcription factor, is correlated with the invasive phenotype of oral squamous cell carcinoma","volume":"33","author":"Hida","year":"1997","journal-title":"Oral Oncol."},{"key":"10.1016\/j.bbadis.2025.167975_bb0070","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/sj.onc.1201331","article-title":"HER2\/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer","volume":"15","author":"Benz","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.bbadis.2025.167975_bb0075","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.18632\/oncotarget.2847","article-title":"Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts","volume":"6","author":"Mesquita","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbadis.2025.167975_bb0080","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2012.20","article-title":"Overexpression of ETV4 is oncogenic in prostate cells through promotion of both cell proliferation and epithelial to mesenchymal transition","volume":"1","author":"Pellecchia","year":"2012","journal-title":"Oncogenesis"},{"key":"10.1016\/j.bbadis.2025.167975_bb0085","doi-asserted-by":"crossref","first-page":"8102","DOI":"10.1158\/0008-5472.CAN-09-0941","article-title":"Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1\/ETS-related protein 81","volume":"69","author":"Shin","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2025.167975_bb0090","doi-asserted-by":"crossref","first-page":"12465","DOI":"10.1073\/pnas.0905931106","article-title":"ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells","volume":"106","author":"Zong","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbadis.2025.167975_bb0095","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1177\/1947601910395578","article-title":"The ETS gene ETV4 is required for anchorage-independent growth and a cell proliferation gene expression program in PC3 prostate cells","volume":"1","author":"Hollenhorst","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.bbadis.2025.167975_bb0100","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13045-020-00943-w","article-title":"ETV4 promotes late development of prostatic intraepithelial neoplasia and cell proliferation through direct and p53-mediated downregulation of p21","volume":"13","author":"Cosi","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbadis.2025.167975_bb0105","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbadis.2025.167975_bb0110","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","article-title":"Concepts of extracellular matrix remodelling in tumour progression and metastasis","volume":"11","author":"Winkler","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2025.167975_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107347","article-title":"Extracellular proteolysis in cancer: proteases, substrates, and mechanisms in tumor progression and metastasis","volume":"300","author":"Radisky","year":"2024","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2025.167975_bb0120","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/jlb.61.6.695","article-title":"Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils","volume":"61","author":"Sallenave","year":"1997","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bbadis.2025.167975_bb0125","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1172\/JCI115255","article-title":"Expression of the secretory leukoprotease inhibitor gene in epithelial cells","volume":"87","author":"Abe","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbadis.2025.167975_bb0130","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1042\/bj2250463","article-title":"Human bronchial leucocyte proteinase inhibitor. Rapid isolation and kinetic analysis with human leucocyte proteinases","volume":"225","author":"Smith","year":"1985","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbadis.2025.167975_bb0135","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1073\/pnas.83.18.6692","article-title":"Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase","volume":"83","author":"Thompson","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbadis.2025.167975_bb0140","doi-asserted-by":"crossref","first-page":"7976","DOI":"10.1016\/S0021-9258(19)39026-X","article-title":"Location of the protease-inhibitory region of secretory leukocyte protease inhibitor","volume":"265","author":"Eisenberg","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2025.167975_bb0145","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0092-8674(00)81880-2","article-title":"Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide","volume":"88","author":"Jin","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2025.167975_bb0150","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1172\/JCI119254","article-title":"Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases","volume":"99","author":"Zhang","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbadis.2025.167975_bb0155","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1043-4666(02)00485-4","article-title":"Effects of secretory leukocyte protease inhibitor on the tumor necrosis factor-alpha production and NF-kappaB activation of lipopolysaccharide-stimulated macrophages","volume":"21","author":"Sano","year":"2003","journal-title":"Cytokine"},{"key":"10.1016\/j.bbadis.2025.167975_bb0160","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ygyno.2011.04.052","article-title":"Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells","volume":"122","author":"Hoskins","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbadis.2025.167975_bb0165","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1136\/gutjnl-2013-306149","article-title":"Human buccal epithelium acquires microbial hyporesponsiveness at birth, a role for secretory leukocyte protease inhibitor","volume":"64","author":"Menckeberg","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2025.167975_bb0170","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cytogfr.2015.12.001","article-title":"Secretory leukocyte protease inhibitor (SLPI), a multifunctional protein in the host defense response","volume":"28","author":"Majchrzak-Gorecka","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bbadis.2025.167975_bb0175","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/1477-7819-12-369","article-title":"Expression of secretory leukocyte protease inhibitor detected by immunohistochemistry correlating with prognosis and metastasis in colorectal cancer","volume":"12","author":"Liu","year":"2014","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.bbadis.2025.167975_bb0180","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1832761","article-title":"Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in colorectal cancer liver metastases and matched primary tumors is associated with a poorer prognosis","volume":"9","author":"Nugteren","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbadis.2025.167975_bb0185","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/1097-0142(20001001)89:7<1448::AID-CNCR6>3.0.CO;2-Q","article-title":"Increased secretory leukoprotease inhibitor in patients with nonsmall cell lung carcinoma","volume":"89","author":"Ameshima","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.bbadis.2025.167975_bb0190","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/ijc.23746","article-title":"Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer","volume":"123","author":"Cheng","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbadis.2025.167975_bb0195","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s12094-014-1232-4","article-title":"Secretory leukocyte protease inhibitor is a proliferation and survival factor for pancreatic cancer cells","volume":"17","author":"Zuo","year":"2015","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.bbadis.2025.167975_bb0200","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12935-015-0182-4","article-title":"SLPI knockdown induced pancreatic ductal adenocarcinoma cells proliferation and invasion","volume":"15","author":"Zhang","year":"2015","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbadis.2025.167975_bb0205","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1349-7006.2009.01076.x","article-title":"Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo","volume":"100","author":"Devoogdt","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbadis.2025.167975_bb0210","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4962137","article-title":"Elevated concentrations of SERPINE2\/protease nexin-1 and secretory leukocyte protease inhibitor in the serum of patients with papillary thyroid cancer","volume":"2017","author":"St\u0119pie\u0144","year":"2017","journal-title":"Dis. Markers"},{"key":"10.1016\/j.bbadis.2025.167975_bb0215","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/ijc.23660","article-title":"Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues","volume":"123","author":"Cimino","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbadis.2025.167975_bb0220","doi-asserted-by":"crossref","first-page":"108292","DOI":"10.18632\/oncotarget.22660","article-title":"Secretory leukocyte protease inhibitor (SLPI) as a potential target for inhibiting metastasis of triple-negative breast cancers","volume":"8","author":"Kozin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbadis.2025.167975_bb0225","doi-asserted-by":"crossref","first-page":"12174","DOI":"10.1038\/s41598-022-16427-5","article-title":"High expression of secretory leukocyte protease inhibitor (SLPI) in stage III micro-satellite stable colorectal cancer is associated with reduced disease recurrence","volume":"12","author":"Nugteren","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2025.167975_bb0230","first-page":"185","article-title":"The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma","volume":"39","author":"Cordes","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbadis.2025.167975_bb0235","first-page":"1793","article-title":"Secretory leukocyte peptidase inhibitor expression and apoptosis effect in oral leukoplakia and oral squamous cell carcinoma","volume":"39","author":"Wang","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbadis.2025.167975_bb0240","doi-asserted-by":"crossref","first-page":"140","DOI":"10.7150\/ijbs.65676","article-title":"SLPI suppresses hepatocellular carcinoma progression via endoplasmic reticulum stress induced apoptosis","volume":"18","author":"Sun","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bbadis.2025.167975_bb0245","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1042\/BST0391433","article-title":"Immunotherapy of prostate cancer: identification of new treatments and targets for therapy, and role of WAP domain-containing proteins","volume":"39","author":"Galustian","year":"2011","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bbadis.2025.167975_bb0250","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/pros.20792","article-title":"Identification of candidate prostate cancer genes through comparative expression-profiling of seminal vesicle","volume":"68","author":"Thompson","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.bbadis.2025.167975_bb0255","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1038\/onc.2016.13","article-title":"Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer","volume":"35","author":"Zheng","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.bbadis.2025.167975_bb0260","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-7-64","article-title":"Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process","volume":"7","author":"Chandran","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbadis.2025.167975_bb0265","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ccr.2005.10.001","article-title":"Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression","volume":"8","author":"Varambally","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbadis.2025.167975_bb0270","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1002\/cam4.5134","article-title":"Up-regulation of secretory leukocyte protease inhibitor in human samples might have a potential role of predicting prostate cancer recurrence and progression after surgery and hormonal therapy","volume":"12","author":"Miyazaki","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbadis.2025.167975_bb0275","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1038\/s41598-023-29484-1","article-title":"Identification and characterization of novel ETV4 splice variants in prostate cancer","volume":"13","author":"Cosi","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2025.167975_bb0280","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/1047322X.1990.10389587","article-title":"Estimation of average concentration in the presence of nondetectable values","volume":"5","author":"Hornung","year":"1990","journal-title":"Appl. Occup. Environ. Hyg."},{"key":"10.1016\/j.bbadis.2025.167975_bb0285","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1196\/annals.1322.044","article-title":"Secretory leukocyte protease inhibitor in cancer development","volume":"1028","author":"Devoogdt","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bbadis.2025.167975_bb0290","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cytogfr.2021.01.005","article-title":"Secretory leukocyte protease inhibitor (SLPI) in mucosal tissues: protects against inflammation, but promotes cancer","volume":"59","author":"Nugteren","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bbadis.2025.167975_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154633","article-title":"Secretory leukocyte protease inhibitor (SLPI) in cancer pathophysiology: mechanisms of action and clinical implications","volume":"248","author":"Zhang","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.bbadis.2025.167975_bb0300","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.devcel.2024.08.008","article-title":"Cell death: revisiting the roads to ruin","volume":"59","author":"Green","year":"2024","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bbadis.2025.167975_bb0305","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nrc.2016.58","article-title":"A fate worse than death: apoptosis as an oncogenic process","volume":"16","author":"Ichim","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbadis.2025.167975_bb0310","first-page":"L269","article-title":"Regulation and activity of secretory leukoprotease inhibitor (SLPI) is altered in smokers","volume":"306","author":"Meyer","year":"2014","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.bbadis.2025.167975_bb0315","doi-asserted-by":"crossref","first-page":"10765","DOI":"10.1093\/nar\/gks888","article-title":"Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions","volume":"40","author":"Decker","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbadis.2025.167975_bb0320","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1365-2249.2000.01269.x","article-title":"Effects of secretory leucocyte protease inhibitor on the production of the anti-inflammatory cytokines, IL-10 and transforming growth factor-beta (TGF-beta), by lipopolysaccharide-stimulated macrophages","volume":"121","author":"Sano","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bbadis.2025.167975_bb0325","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1470-2045(06)70579-4","article-title":"Proteins with whey-acidic-protein motifs and cancer","volume":"7","author":"Bouchard","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbadis.2025.167975_bb0330","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1086\/302994","article-title":"Evidence for a prostate cancer-susceptibility locus on chromosome 20","volume":"67","author":"Berry","year":"2000","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbadis.2025.167975_bb0335","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1086\/318797","article-title":"Analysis of the prostate cancer-susceptibility locus HPC20 in 172 families affected by prostate cancer","volume":"68","author":"Bock","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbadis.2025.167975_bb0340","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s004390100513","article-title":"Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families","volume":"108","author":"Zheng","year":"2001","journal-title":"Hum. Genet."},{"key":"10.1016\/j.bbadis.2025.167975_bb0345","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2016.05.028","article-title":"Human uterus myoma and gene expression profiling: a novel in vitro model for studying secretory leukocyte protease inhibitor-mediated tumor invasion","volume":"379","author":"Mikami","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbadis.2025.167975_bb0350","first-page":"527","article-title":"Secretory leukocyte protease inhibitor is associated with MMP-2 and MMP-9 to promote migration and invasion in SNU638 gastric cancer cells","volume":"28","author":"Choi","year":"2011","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bbadis.2025.167975_bb0355","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/boc.201300075","article-title":"Secretory leukocyte protease inhibitor (SLPI) expression downregulates E-cadherin, induces \u03b2-catenin re-localisation and triggers apoptosis-related events in breast cancer cells","volume":"106","author":"Rosso","year":"2014","journal-title":"Biol. Cell."},{"key":"10.1016\/j.bbadis.2025.167975_bb0360","first-page":"1495","article-title":"SLPI promotes the gastric cancer growth and metastasis by regulating the expression of P53, Bcl-2 and Caspase-8","volume":"21","author":"Du","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.bbadis.2025.167975_bb0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12672-022-00535-9","article-title":"Inhibition of secretory leukocyte protease inhibitor (SLPI) promotes the PUMA-mediated apoptosis and chemosensitivity to cisplatin in colorectal cancer cells","volume":"14","author":"Wei","year":"2023","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bbadis.2025.167975_bb0370","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11626-999-0115-4","article-title":"A new human prostate carcinoma cell line, 22Rv1","volume":"35","author":"Sramkoski","year":"1999","journal-title":"In Vitro Cell. Dev. Biol. Anim."},{"key":"10.1016\/j.bbadis.2025.167975_bb0375","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.cell.2018.10.019","article-title":"Genomic hallmarks and structural variation in metastatic prostate Cancer","volume":"175","author":"Quigley","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2025.167975_bb0380","series-title":"Exploratory Study of SLPI Expression in Human Prostate cancer Patients., in","article-title":"SLPI: A novel biomarker of prostate Cancer","author":"NCT04854343, Observational Prospective Study","year":"2020"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443925003230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443925003230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:48:09Z","timestamp":1788295689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443925003230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":76,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0925443925003230"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2025.167975","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ETV4 and ETV1-mediated downregulation of the secretory leukocyte protease inhibitor contributes to the indolent phenotype of early-stage prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2025.167975","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"167975"}}